Actively Recruiting
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Led by Milton S. Hershey Medical Center · Updated on 2025-09-19
52
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
Sponsors
M
Milton S. Hershey Medical Center
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
CONDITIONS
Official Title
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women of all races
- Age 18 to 65 years
- Body mass index (BMI) between 30-45 kg/m2
- Pre-hypertension (two or more seated blood pressure readings >120/80 mmHg) or hypertension (two or more seated blood pressure readings >130/80 mmHg or use of antihypertensive medications)
- Capable of giving informed consent
- Fluent in written and spoken English
- Satisfactory history and physical exam
You will not qualify if you...
- Age 17 years or younger or 66 years or older
- Taking more than two antihypertensive medications
- Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
- Pregnant or nursing women
- Women taking hormone replacement therapy within 6 months
- Decisional impairment
- Prisoners
- Alcohol or drug abuse
- Current smokers
- Highly trained athletes
- Subjects with more than 5% weight change in the past 3 months
- Body mass index (BMI) over 45 kg/m2
- Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
- History of serious cardiovascular disease (e.g., recent heart attack, symptomatic coronary artery disease, angina, significant arrhythmia, heart failure, blood clots, severe heart valve issues, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., stroke, transient ischemic attack)
- History or presence of immunological or blood disorders
- Impaired liver function (AST or ALT levels more than twice the upper normal limit)
- Impaired kidney function (serum creatinine >2.0 mg/dl)
- Anemia
- Treatment with drugs increasing sympathetic activity (e.g., serotonin-norepinephrine reuptake inhibitors or stimulants)
- Treatment with phosphodiesterase-5 inhibitors
- Treatment with anticoagulants (e.g., warfarin)
- Chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
- Treatment with any investigational drug in the month before the study
- Inability to give or withdraw informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Actively Recruiting
Research Team
A
Aimee Cauffman, RN
CONTACT
A
Amy Arnold, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here